Chimerix Promotes Michelle LaSpaluto to Chief Financial Officer
04 December 2023 - 11:00PM
Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission
is to develop medicines that meaningfully improve and extend the
lives of patients facing deadly diseases, today announced the
promotion of Michelle LaSpaluto, Vice President of Corporate
Financial Planning and Investor Relations, to Chief Financial
Officer effective December 1, 2023.
“We are excited to announce this well-deserved promotion as
Michelle has the proven financial and leadership skills to advance
Chimerix into our next growth phase and beyond,” said Mike
Andriole, Chief Executive Officer of Chimerix. “Over the last
decade, Michelle has grown into a leader within the company having
touched every area core to the CFO role, including capital raising,
accounting, investor relations, internal controls and supporting
business development transactions. Importantly, Michelle’s deep
familiarity with our operating structure and programs will enable
her quick transition to this expanded responsibility. I look
forward to continuing my partnership with her in this new position
and am confident in her ongoing success.”
“I am honored to step into the CFO role at this point in
Chimerix’s growth trajectory. We have an exciting future ahead as
we advance our imipridone pipeline and give hope to patients faced
with life limiting cancers,” said Ms. LaSpaluto. “We have an
exceptional team of talented and dedicated leaders and I look
forward to continuing to work together toward building Chimerix
into a leading oncology company.”
Since joining Chimerix in 2011, Ms. LaSpaluto has served in
roles of increasing responsibility spanning finance, accounting,
project planning, investor relations and strategy, most recently as
Vice President Corporate Financial Planning and Investor Relations.
Prior to joining Chimerix, Ms. LaSpaluto was Senior Director of
Accounting at AlphaVax. She began her career at Coopers &
Lybrand in Detroit before transferring to Raleigh with
PriceWaterhouseCoopers. Ms. LaSpaluto holds an M.B.A. from East
Carolina University and a B.A. in Accounting from Michigan State
University.
About Chimerix Chimerix is a biopharmaceutical
company with a mission to develop medicines that meaningfully
improve and extend the lives of patients facing deadly diseases.
The Company’s most advanced clinical-stage development program,
ONC201, is in development for H3 K27M-mutant glioma.
CONTACT: Will
O’ConnorStern Investor Relations212-362-1200ir@chimerix.com
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Apr 2024 to May 2024
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From May 2023 to May 2024